Male glucocorticoid-induced osteoporosis: teriparatide more effective than risedronate .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.187092 men with glucocorticoid-induced osteoporosis (GIO) were randomized to receive either daily injections of 20 ug teriparatide or weekly oral tablets of 35 mg risedronate to determine the effects of these treatments on improvements in bone mineral density (BMD), as assessed with dual X‐ray absorptiometry (DXA) and high-resolution quantitative computed tomography (HRQCT). Results indicated that, although both treatments were generally similar at 6 months, improvements in bone mineral density significantly favoured the teriparatide group, compared to the risedronate group at 18 months. Similar trends were observed for vertebral strength and stiffness. Complications and adverse events were also similar for both groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
